Screener
Inhibrx Biosciences, Inc. INBX Nonmonetary Transaction, Gain (Loss) Recognized on Transfer
Discontinued — last reported Q4 '25
Nonmonetary Transaction, Gain (Loss) Recognized on Transfer at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer.
The source filing: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026.
- Filed
- Mar 19, 2026, 4:00 PM EDT
- Fiscal year
- FY2025
- Accession
- 0002007919-26-000006
| Line item | YEAR ENDEDDECEMBER 31, 2025 | YEAR ENDEDDECEMBER 31, 2024 |
|---|---|---|
| Total operating expenses | 136,325 | 331,648 |
| Loss from operations | (135,025) | (331,448) |
| Other income (expense): | ||
| Gain related to transaction with Acquirer | — | 2,021,498 |
| Interest expense | (12,196) | (13,491) |
| Interest income | 7,549 | 10,940 |
| Other income (expense), net | (381) | 75 |
| Total other income (expense) | (5,028) | 2,019,022 |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Inhibrx Biosciences, Inc.'s nonmonetary transaction, gain (loss) recognized on transfer?
- Inhibrx Biosciences, Inc. (INBX) reported nonmonetary transaction, gain (loss) recognized on transfer of $0 in Q4 2025.
- What does nonmonetary transaction, gain (loss) recognized on transfer mean?
- This metric represents the net gain or loss recognized from the exchange of non-cash assets or liabilities, such as equipment, intellectual property, or equity interests. It reflects the impact of non-routine transactions on the company's operating results, excluding standard cash-based operational activities. Investors monitor this to isolate the impact of asset divestitures or strategic exchanges from core research and development performance.
Ask your AI about Inhibrx Biosciences, Inc.'s nonmonetary transaction, gain (loss) recognized on transfer.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude